Nikang Therapeutics, Inc.
Clinical trials sponsored by Nikang Therapeutics, Inc., explained in plain language.
-
New pill targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis is the first study in people to test a new oral medication called NKT3964. The main goals are to find a safe dose and see if the drug shows early signs of shrinking tumors in adults with advanced cancers that have spread and no longer respond to standard treatments. The stud…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
First patients to try new pill targeting Hard-to-Treat cancers
Disease control Recruiting nowThis is the first study in people testing a new oral medication called NKT5097 for adults with advanced or metastatic solid tumors, with a focus on certain breast, ovarian, and uterine cancers. The main goals are to find a safe dose, see how the body processes the drug, and check…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC